JP2020526584A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526584A5
JP2020526584A5 JP2020522279A JP2020522279A JP2020526584A5 JP 2020526584 A5 JP2020526584 A5 JP 2020526584A5 JP 2020522279 A JP2020522279 A JP 2020522279A JP 2020522279 A JP2020522279 A JP 2020522279A JP 2020526584 A5 JP2020526584 A5 JP 2020526584A5
Authority
JP
Japan
Prior art keywords
seq
cdr2
cdr3
antibody
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020522279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526584A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/039445 external-priority patent/WO2019005756A1/en
Publication of JP2020526584A publication Critical patent/JP2020526584A/ja
Publication of JP2020526584A5 publication Critical patent/JP2020526584A5/ja
Priority to JP2023088505A priority Critical patent/JP2023116554A/ja
Priority to JP2025013074A priority patent/JP2025069272A/ja
Pending legal-status Critical Current

Links

JP2020522279A 2017-06-28 2018-06-26 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用 Pending JP2020526584A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023088505A JP2023116554A (ja) 2017-06-28 2023-05-30 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用
JP2025013074A JP2025069272A (ja) 2017-06-28 2025-01-29 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762525993P 2017-06-28 2017-06-28
US62/525,993 2017-06-28
PCT/US2018/039445 WO2019005756A1 (en) 2017-06-28 2018-06-26 CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023088505A Division JP2023116554A (ja) 2017-06-28 2023-05-30 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用

Publications (2)

Publication Number Publication Date
JP2020526584A JP2020526584A (ja) 2020-08-31
JP2020526584A5 true JP2020526584A5 (https=) 2021-08-05

Family

ID=64742639

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020522279A Pending JP2020526584A (ja) 2017-06-28 2018-06-26 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用
JP2023088505A Pending JP2023116554A (ja) 2017-06-28 2023-05-30 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用
JP2025013074A Withdrawn JP2025069272A (ja) 2017-06-28 2025-01-29 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023088505A Pending JP2023116554A (ja) 2017-06-28 2023-05-30 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用
JP2025013074A Withdrawn JP2025069272A (ja) 2017-06-28 2025-01-29 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用

Country Status (5)

Country Link
US (2) US11613588B2 (https=)
EP (1) EP3645041A4 (https=)
JP (3) JP2020526584A (https=)
CA (1) CA3068672A1 (https=)
WO (1) WO2019005756A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526584A (ja) 2017-06-28 2020-08-31 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用
WO2020076799A1 (en) 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
MA55080A (fr) * 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
BR112021020867A2 (pt) * 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
JP2023506465A (ja) 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
AU2022207454A1 (en) * 2021-01-15 2023-06-22 R.P. Scherer Technologies, Llc Camptothecine antibody-drug conjugates and methods of use thereof
CA3217372A1 (en) * 2021-05-14 2022-11-17 Masoud TAVAZOIE Mertk peptides and uses thereof
US20240279341A1 (en) 2021-06-16 2024-08-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
JP2024527493A (ja) 2021-06-16 2024-07-25 アレクトル エルエルシー 一価の抗ＭｅｒＴＫ抗体及びその使用方法
WO2025070337A1 (ja) * 2023-09-25 2025-04-03 アステラス製薬株式会社 抗ＭｅｒＴＫアゴニスト抗体、抗ＭｅｒＴＫ二重特異性抗体、及びその使用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE60042789D1 (de) 1999-11-29 2009-10-01 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
JP2008522162A (ja) 2004-11-24 2008-06-26 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド Ｍｅｒの診断用および治療用の作用薬
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2277044B1 (en) 2008-05-13 2015-06-17 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
WO2012021942A1 (en) 2010-08-19 2012-02-23 Howard Florey Institute Tam receptors and tam receptor ligands in detection and modulation of neuropathological disease
US20150315552A1 (en) * 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
TWI731535B (zh) * 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
JP2020526584A (ja) 2017-06-28 2020-08-31 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用
MA55080A (fr) * 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées

Similar Documents

Publication Publication Date Title
JP2020526584A5 (https=)
FI3930847T3 (fi) Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
JP2022101693A5 (https=)
JP2023022328A5 (https=)
RU2016117810A (ru) Конъюгаты белок-полимер-лекарственное средство
HRP20200283T1 (hr) Protutijela koja se vežu na axl
HRP20171789T1 (hr) Konjugati humanog protutijela s lijekom protiv tkivnog faktora
JP2012522513A5 (https=)
JP2020502271A5 (https=)
HRP20200551T1 (hr) Axl-specifični konjugati protutijelo-lijek za liječenje raka
HRP20220172T1 (hr) Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
JP2012522512A5 (https=)
JP2018520991A5 (https=)
JP2019532056A5 (https=)
RU2008141171A (ru) Анти-тат226 антитела и иммуноконъюгаты
JP2014520088A5 (https=)
JP2010535713A5 (https=)
WO2022228563A1 (zh) 靶向Nectin-4的抗体药物偶联物及其制备方法和用途
CN112543752A (zh) 连接子、含连接子的抗体偶联药物及连接子的用途
JP2018501781A5 (https=)
JP2014522850A5 (https=)
JP2017522871A5 (https=)
JPWO2021213434A5 (https=)
JP2016538318A5 (https=)